Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC) * Disease must have progressed after at least 2 prior chemotherapy regimens for NSCLC * Patients must have measurable or nonmeasurable disease * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST and ALT no greater than 3 times ULN (5 times ULN in patients with liver disease) * Creatinine less than 1.5 times ULN or calculated creatinine clearance greater than 50 mL/min * More than 3 weeks since prior chemotherapy, radiotherapy, immunotherapy or other investigational drug use * Recovered from all prior therapy * Fertile patients must use effective contraception * Age \>= 18 * ECOG performance status of 0-1 Exclusion Criteria: * Prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable and off therapy for at least 2 months * Active second malignancy * Clinically evident congestive heart failure, serious cardiac arrhythmias, or symptoms of coronary heart disease * Prior radiotherapy to the only site of measurable or evaluable disease unless there is evidence of disease progression in that site * Prior exposure to a ras pathway inhibitor (e.g., farnesyl transferase inhibitor) * Concurrent medications known to be metabolized by the liver with a narrow therapeutic index, including the following: * Ketoconazole * Itraconazole * Quinidine * Digoxin * Cyclosporine * Ritonavir * Grapefruit products * Carbamazepine * Phenytoin * Phenobarbital * Pregnant or nursing * Clinically serious active infection * Medical conditions, substance abuse or psychological/social situation that would preclude study participation